Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Safety
  4. Fast Track Articles
  5. Fast Track Article
image of Vorasidenib: A Milestone in Targeted Therapy for IDH-Mutant Lower Grade Gliomas - Efficacy, Emerging Safety Concerns, and the Call for Comprehensive Safety Evaluation

There is no abstract available.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863355533241202110934
2024-12-13
2025-01-27

  • From This Site

    /content/journals/cds/10.2174/0115748863355533241202110934
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Berger T.R. Wen P.Y. Lang-Orsini M. Chukwueke U.N. World Health Organization 2021 classification of central nervous system tumors and implications for therapy for adult-type gliomas. JAMA Oncol. 2022 8 10 1493 1501 10.1001/jamaoncol.2022.2844 36006639
    [Google Scholar]
  2. Mellinghoff I.K. Penas-Prado M. Peters K.B. Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial. Clin. Cancer Res. 2021 27 16 4491 4499 10.1158/1078‑0432.CCR‑21‑0611 34078652
    [Google Scholar]
  3. Bombino A. Magnani M. Conti A. A promising breakthrough: The potential of Vorasidenib in the treatment of low-grade glioma. Curr. Mol. Pharmacol. 2024 17 e18761429290327 10.2174/0118761429290327240222061812 38425121
    [Google Scholar]
  4. Mellinghoff I.K. van den Bent M.J. Blumenthal D.T. Vorasidenib in IDH1 or IDH2-mutant low-grade glioma. N. Engl. J. Med. 2023 389 7 589 601 10.1056/NEJMoa2304194 37272516
    [Google Scholar]
  5. FDA approves vorasidenib for Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. 2024 Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vorasidenib-grade-2-astrocytoma-or-oligodendroglioma-susceptible-idh1-or-idh2-mutation
  6. Highlights of prescribing information Voranigo® (Vorasidenib). 2024 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf
/content/journals/cds/10.2174/0115748863355533241202110934
Loading

  • Article Type:     Editorial

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test